Slowly but surely we are learning more about the roles of family history and familial genetics (heredity) in determining risk for prostate cancer — and most especially risk for clinically significant forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: family, germline, heredity, history, mutation, risk | 3 Comments »
According to a media release issued by AstraZeneca and Merck on Friday evening, olaparib (Lynparza) has shown “a statistically significant and clinically meaningful improvement in … overall survival (OS)” in men with metastatic, castration-resistant prostate cancer (mCRPC) and BRCA1/2 or ATM gene mutations (homologous repair gene mutations or HRRm). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: gene, Lynparza, mCRPC, mutation, olaparib, Profound, repair | 11 Comments »
A newly published paper in the Journal of Clinical Oncology has confirmed — based on a prospective study (as opposed to retrospective data) — that there is a strong risk association between a germline mutation of the BRCA2 gene and risk for metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: BRCA2, germline, mutation, screening | 1 Comment »
A newly published article in the Journal of the National Cancer Institute has suggested that men carrying a particular genetic mutation in the kallikrein 6 gene (KLK-6) have an increased risk for aggressive, clinically significant prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: aggressive, genetic, kallikrein, KLK-6, mutation, risk | 2 Comments »
An article with the above title appears to be scheduled for upcoming publication in Scientific American but is already available on line on the Scientific American web site. It may be of interest to a number of our readers. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: genetics, Management, mutation, risk | 4 Comments »
A recent article in the International Journal of Cancer lays out a possible future scenario for prostate cancer risk assessment that takes specific account of familial and hereditary risks for clinically significant prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: allele, Diagnosis, gene, heredity, market, mutation, risk | Leave a comment »
It is not entirely surprising to come across a paper suggesting that male carriers of the BRCA1/2 genes are at risk for worse post-treatment outcomes than non-carriers of these genes after standard forms of first-line treatment for prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: BRCA1/2, mutation, outcome, risk, Treatment | 2 Comments »
A new study has confirmed an initial finding that the rare G84E mutation (also known as rs138213197) in the HOXB13 gene is a significant driver of risk for prostate cancer among men with a family history of the disease. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: familial, hereditary, mutation, risk | 1 Comment »
A Letter to the Editor just published in the journal Nature Genetics has suggested that that so-called SPOP mutations may be responsible for between 6 and 15 percent of the prostate cancers diagnosed in the USA each year. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: gene, mutation, SPOP, subtype, targeted | Leave a comment »
A new paper in the Proceedings of the National Academy of Sciences suggests the existence of a subset of “hypermutated” cell lines in some forms of aggressive prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: aggressive, genetics, hypermutation, mutation, variants | Leave a comment »
According to a new paper in the journal Cell, researchers at the Sanger Institute at Cambridge, in England, believe they have discovered a completely new mechanism for the initial development of about 2 or 3 percent of all cancers. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: cause, chromosome, chromothripsis, DNA, mutation | Leave a comment »
Today’s news reports deal with such matters as:
Filed under: Drugs in development, Management, Treatment, Uncategorized | Tagged: abiraterone, androgen resistance, AT-101, CTC, ERG, mutation, radical prostatectomy | Leave a comment »
According to another Reuters report, men who develop prostate cancer and who carry one of three possible hereditary mutations to the so-called breast cancer genes BRCA1 and BRCA2 appear to be at particularly high risk for an aggressive form of the disease. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: aggressive disease, BRCA1, BRCA2, mutation, risk | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 